119 related articles for article (PubMed ID: 10987228)
1. Can axillary dissection be avoided by improved molecular biological diagnosis?
Lindahl T; Engel G; Ahlgren J; Klaar S; Bjöhle J; Lindman H; Andersson J; von Schoultz E; Bergh J
Acta Oncol; 2000; 39(3):319-26. PubMed ID: 10987228
[TBL] [Abstract][Full Text] [Related]
2. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
[TBL] [Abstract][Full Text] [Related]
3. Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
8. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
9. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
10. Predictive parameters for internal mammary node drainage in patients with early breast cancer.
Lukesova L; Vrana D; Gatek J; Koranda P; Cwiertka K; Radova L; Melichar B; Prouzova Z; Sramek V; Svach I
Tumori; 2014; 100(3):254-8. PubMed ID: 25076234
[TBL] [Abstract][Full Text] [Related]
11. Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).
Agresti R; Martelli G; Sandri M; Tagliabue E; Carcangiu ML; Maugeri I; Pellitteri C; Ferraris C; Capri G; Moliterni A; Bianchi G; Mariani G; Trecate G; Lozza L; Langer M; Rampa M; Gennaro M; Greco M; Menard S; Pierotti MA
Cancer; 2014 Mar; 120(6):885-93. PubMed ID: 24323615
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection.
Kamath VJ; Giuliano R; Dauway EL; Cantor A; Berman C; Ku NN; Cox CE; Reintgen DS
Arch Surg; 2001 Jun; 136(6):688-92. PubMed ID: 11387010
[TBL] [Abstract][Full Text] [Related]
13. Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study.
Folli S; Falco G; Mingozzi M; Buggi F; Curcio A; Ferrari G; Taffurelli M; Regolo L; Nanni O
Minerva Chir; 2016 Apr; 71(2):73-9. PubMed ID: 26207566
[TBL] [Abstract][Full Text] [Related]
14. [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J; Polgár C; Péley G; Németh G
Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
[TBL] [Abstract][Full Text] [Related]
15. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
[TBL] [Abstract][Full Text] [Related]
17. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
[TBL] [Abstract][Full Text] [Related]
18. [Axillary lymph node dissection in clinically node-positive breast cancer].
Iwata H; Miura S
Nihon Geka Gakkai Zasshi; 2002 Nov; 103(11):831-4. PubMed ID: 12478861
[TBL] [Abstract][Full Text] [Related]
19. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.
Veronesi U; Paganelli G; Galimberti V; Viale G; Zurrida S; Bedoni M; Costa A; de Cicco C; Geraghty JG; Luini A; Sacchini V; Veronesi P
Lancet; 1997 Jun; 349(9069):1864-7. PubMed ID: 9217757
[TBL] [Abstract][Full Text] [Related]
20. [Demonstration of the sentinel lymph node in axillary dissection for breast cancer].
Salmon RJ; Fried D
Presse Med; 1998 Mar; 27(11):509-12. PubMed ID: 9767960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
